Extrapulmonary Small Cell Carcinoma of the Bladder

Shahab, Nasir

doi:10.1053/j.seminoncol.2006.10.025

Cited by 35 publications

(28 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4,6,9,[13][14][15]24 However, unlike most previous studies the majority of patients were treated with P/E. Thus, the poor outcomes of these patients cannot be attributed to outdated chemotherapy.…”

Section: Discussionmentioning

confidence: 89%

“…In addition, this tumor has been noted to arise from a diverse number of primary sites including head and neck (H&N), genitourinary (GU), gynecologic (GYN), and gastrointestinal (GI). [1][2][3][4][5][6][7][8][9] Given the rarity of this disease, no large randomized trials exist to guide the treatment of EPSCC. Thus, treatment approaches have typically been extrapolated from trials designed for the more common small cell lung carcinoma (SCLC).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Limited-Stage Extrapulmonary Small Cell Carcinoma: Outcomes After Modern Chemotherapy and Radiotherapy

Soto

Eisbruch

2007

The Cancer Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 89%

mentioning

confidence: 99%

Limited-Stage Extrapulmonary Small Cell Carcinoma: Outcomes After Modern Chemotherapy and Radiotherapy

Soto

Eisbruch

2007

The Cancer Journal

View full text Add to dashboard Cite

show abstract

“…There are a lot of controversies with regard to the pathological origin of EPSCC. While it is traditionally considered that both EPSCC and SCLC originate from diffused neuroendocrine system cells mainly comprising APUD cells [17], others maintain that EPSCC originates from stem cells with multiple differentiated potential [18]. Although EPSCC shows certain different biological behaviors and prognoses than SCLC, it has a similar staging system in the sense that it is classified as either 'limited stage' in which all sites of disease can be encompassed within a tolerable radiation field, or 'extensive stage' [7,19].…”

Section: Discussionmentioning

confidence: 99%

Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

Jin

Wang²,

Chen³

et al. 2011

Onkologie

View full text Add to dashboard Cite

Background: The regimen of weekly irinotecan plus cisplatin (IP) is used for treatment of small cell lung cancer (SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of weekly IP in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma (EPSCC). Patients and Methods: 15 patients with previously untreated extensive-stage EPSCC were enrolled. They received 60 mg/m2 of irinotecan on days 1, 8 and 15, and 25 mg/m² of cisplatin days 1–3. This regimen was given every 28 days, and efficacy was evaluated after 2 cycles. Results: Objective responses were observed in 10 patients (66.7%), including 3 complete responses (20%) and 7 partial responses (46.7%). The median time to tumor progression was 4.5 months, the median survival time was 11.4 months, and the 1-year survival rate was 46.7%. Toxicities were relatively mild, and there were no treatment-related deaths. Conclusions: Weekly IP has significant activity in extensive-stage EPSCC. The regimen was well tolerated, with acceptable myelosuppression and treatment-related diarrhea.

show abstract

“…The median age of EPSCC patients was 53-72 years, and the male-to-female ratio was 1.03-1.4:1 [3,4,5,15,16,17]. Similar to SCLC, EPSCC includes 2 stages.…”

Section: Discussionmentioning

confidence: 99%

“…Extrapulmonary small cell carcinoma (EPSCC), which accounts for only 2.5-4% of all small cell carcinomas, occurs in many extrapulmonary sites such as the gastrointestinal tract, the head and neck, and the genitourinary system [1,2,3,4,5]. EPSCC of unknown primary has also been reported [6] and accounts for 8-31%.…”

Section: Introductionmentioning

confidence: 99%

Primary Intracranial Small Cell Carcinoma: A Case Report and Review of the Literature

et al. 2013

View full text Add to dashboard Cite

Background: Extrapulmonary small cell carcinoma is a distinct clinicopathological entity accounting for only 2.5-4% of small cell carcinomas. Here we present a case of primary intracranial small cell carcinoma. Case Report: A 69-year-old woman with an isolated brain lesion presented with progressive headaches, confusion, nausea, and vomiting. A magnetic resonance imaging scan of the brain revealed a 4 × 3 × 5-cm solitary cystic tumor in the right frontoparietal lobe, accompanied by a midline shift. The mass was resected and pathologically proven to be a small cell carcinoma. The patient was given adjuvant radiotherapy but refused any chemotherapy. At the 12-month follow-up the patient was alive and well. Conclusion: Primary intracranial small cell carcinoma presenting as an isolated lesion is extremely rare. While there are no standard treatment guidelines for these patients, the authors believe multimodality treatment including tumorectomy and postoperative radiotherapy should be recommended.

show abstract

Extrapulmonary Small Cell Carcinoma of the Bladder

Cited by 35 publications

References 73 publications

Limited-Stage Extrapulmonary Small Cell Carcinoma: Outcomes After Modern Chemotherapy and Radiotherapy

Limited-Stage Extrapulmonary Small Cell Carcinoma: Outcomes After Modern Chemotherapy and Radiotherapy

Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

Primary Intracranial Small Cell Carcinoma: A Case Report and Review of the Literature

Contact Info

Product

Resources

About